GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » American Oncology Network Inc (NAS:AONCW) » Definitions » Cash, Cash Equivalents, Marketable Securities

American Oncology Network (American Oncology Network) Cash, Cash Equivalents, Marketable Securities : $105.05 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is American Oncology Network Cash, Cash Equivalents, Marketable Securities?

American Oncology Network's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($77.69 Mil) to Dec. 2023 ($63.93 Mil) but then increased from Dec. 2023 ($63.93 Mil) to Mar. 2024 ($105.05 Mil).

American Oncology Network's annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($27.35 Mil) to Dec. 2022 ($36.78 Mil) and increased from Dec. 2022 ($36.78 Mil) to Dec. 2023 ($63.93 Mil).


American Oncology Network Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for American Oncology Network's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Oncology Network Cash, Cash Equivalents, Marketable Securities Chart

American Oncology Network Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
- 27.35 36.78 63.93

American Oncology Network Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial 36.78 - 77.69 63.93 105.05

American Oncology Network Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


American Oncology Network  (NAS:AONCW) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


American Oncology Network Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of American Oncology Network's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


American Oncology Network (American Oncology Network) Business Description

Traded in Other Exchanges
Address
10485 NE 6th Street, Unit 3930, Bellevue, WA, USA, 98004
American Oncology Network Inc Formerly American Oncology Network LLC is an alliance of physicians and seasoned healthcare leaders who provide comprehensive oncology services through 24 oncology practices located in Arkansas, Louisiana, Indiana, Virginia, Ohio, Nevada, Iowa, Missouri, Washington, North Carolina, Michigan, Maryland, South Carolina, Arizona, and Georgia. The Company also provides expertise in drug procurement and payor contracting, along with practice diversification through centralized laboratory and pathology services, as well as specialty pharmacy services.